Norges Bank Invests $6.91 Million in Xencor, Inc. (NASDAQ:XNCR)

Norges Bank bought a new position in shares of Xencor, Inc. (NASDAQ:XNCRFree Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 325,439 shares of the biopharmaceutical company’s stock, valued at approximately $6,909,000. Norges Bank owned approximately 0.53% of Xencor at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Primecap Management Co. CA increased its stake in Xencor by 5.6% in the 3rd quarter. Primecap Management Co. CA now owns 8,184,206 shares of the biopharmaceutical company’s stock valued at $164,912,000 after purchasing an additional 433,354 shares in the last quarter. Armistice Capital LLC increased its stake in Xencor by 65.7% in the 3rd quarter. Armistice Capital LLC now owns 1,478,000 shares of the biopharmaceutical company’s stock valued at $29,782,000 after purchasing an additional 586,000 shares in the last quarter. Invesco Ltd. increased its stake in Xencor by 4.6% in the 3rd quarter. Invesco Ltd. now owns 555,809 shares of the biopharmaceutical company’s stock valued at $11,200,000 after purchasing an additional 24,303 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Xencor by 6.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 520,698 shares of the biopharmaceutical company’s stock valued at $11,054,000 after purchasing an additional 32,251 shares in the last quarter. Finally, Hudson Bay Capital Management LP increased its stake in Xencor by 144.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company’s stock valued at $4,685,000 after purchasing an additional 137,500 shares in the last quarter.

Insider Transactions at Xencor

In related news, CEO Bassil I. Dahiyat sold 2,741 shares of Xencor stock in a transaction on Monday, March 11th. The stock was sold at an average price of $23.50, for a total value of $64,413.50. Following the transaction, the chief executive officer now owns 351,894 shares in the company, valued at $8,269,509. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Bassil I. Dahiyat sold 2,741 shares of Xencor stock in a transaction on Monday, March 11th. The stock was sold at an average price of $23.50, for a total value of $64,413.50. Following the transaction, the chief executive officer now owns 351,894 shares in the company, valued at $8,269,509. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP John R. Desjarlais sold 1,280 shares of Xencor stock in a transaction on Monday, March 11th. The shares were sold at an average price of $23.50, for a total value of $30,080.00. Following the completion of the transaction, the vice president now owns 186,433 shares in the company, valued at approximately $4,381,175.50. The disclosure for this sale can be found here. Insiders have sold 5,720 shares of company stock worth $134,420 over the last quarter. 5.23% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on XNCR shares. Piper Sandler reaffirmed a “neutral” rating and issued a $24.00 price objective (down from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. StockNews.com raised Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. BTIG Research dropped their price target on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, April 16th. BMO Capital Markets dropped their price target on Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Finally, Wedbush raised their price target on Xencor from $34.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.43.

View Our Latest Stock Analysis on XNCR

Xencor Price Performance

XNCR stock opened at $21.91 on Friday. Xencor, Inc. has a 52-week low of $16.49 and a 52-week high of $27.48. The stock’s fifty day simple moving average is $21.88 and its 200-day simple moving average is $21.35. The company has a quick ratio of 7.08, a current ratio of 7.08 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -10.00 and a beta of 0.82.

Xencor (NASDAQ:XNCRGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.28). Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. The business had revenue of $12.80 million for the quarter, compared to analyst estimates of $23.07 million. During the same quarter last year, the business earned ($1.02) EPS. Xencor’s revenue for the quarter was down 32.3% compared to the same quarter last year. Equities research analysts expect that Xencor, Inc. will post -3.5 EPS for the current year.

Xencor Profile

(Free Report)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Featured Stories

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.